Compare GSK Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs SUN PHARMA - Comparison Results

GSK PHARMA     Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA SUN PHARMA GSK PHARMA/
SUN PHARMA
 
P/E (TTM) x 52.1 27.9 187.1% View Chart
P/BV x 11.0 2.4 455.8% View Chart
Dividend Yield % 1.4 0.7 217.3%  

Financials

 GSK PHARMA   SUN PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-19
SUN PHARMA
Mar-19
GSK PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,595679 529.6%   
Low Rs1,253375 333.8%   
Sales per share (Unadj.) Rs184.7121.1 152.4%  
Earnings per share (Unadj.) Rs26.313.4 196.6%  
Cash flow per share (Unadj.) Rs29.220.7 141.0%  
Dividends per share (Unadj.) Rs20.002.75 727.3%  
Dividend yield (eoy) %0.80.5 158.1%  
Book value per share (Unadj.) Rs126.3172.6 73.2%  
Shares outstanding (eoy) m169.402,399.26 7.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x13.14.4 301.7%   
Avg P/E ratio x92.239.4 234.0%  
P/CF ratio (eoy) x83.125.5 326.2%  
Price / Book Value ratio x19.23.1 628.3%  
Dividend payout %76.120.6 370.0%   
Avg Mkt Cap Rs m410,6261,264,650 32.5%   
No. of employees `0005.017.5 28.3%   
Total wages/salary Rs m5,37259,671 9.0%   
Avg. sales/employee Rs Th6,306.716,608.1 38.0%   
Avg. wages/employee Rs Th1,083.13,409.6 31.8%   
Avg. net profit/employee Rs Th898.01,833.8 49.0%   
INCOME DATA
Net Sales Rs m31,281290,659 10.8%  
Other income Rs m1,02310,255 10.0%   
Total revenues Rs m32,304300,914 10.7%   
Gross profit Rs m6,00963,076 9.5%  
Depreciation Rs m48617,533 2.8%   
Interest Rs m65,553 0.1%   
Profit before tax Rs m6,54050,246 13.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m287-12,144 -2.4%   
Tax Rs m2,3736,009 39.5%   
Profit after tax Rs m4,45432,093 13.9%  
Gross profit margin %19.221.7 88.5%  
Effective tax rate %36.312.0 303.4%   
Net profit margin %14.211.0 129.0%  
BALANCE SHEET DATA
Current assets Rs m20,061310,692 6.5%   
Current liabilities Rs m14,543173,396 8.4%   
Net working cap to sales %17.647.2 37.3%  
Current ratio x1.41.8 77.0%  
Inventory Days Days5799 57.3%  
Debtors Days Days14112 12.6%  
Net fixed assets Rs m14,343232,477 6.2%   
Share capital Rs m1,6942,399 70.6%   
"Free" reserves Rs m19,704411,691 4.8%   
Net worth Rs m21,398414,091 5.2%   
Long term debt Rs m215,226 0.0%   
Total assets Rs m39,113646,938 6.0%  
Interest coverage x1,091.010.0 10,856.6%   
Debt to equity ratio x00 0.3%  
Sales to assets ratio x0.80.4 178.0%   
Return on assets %11.45.8 196.0%  
Return on equity %20.87.8 268.6%  
Return on capital %31.910.2 314.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53466,025 0.8%   
Fx outflow Rs m7,09138,610 18.4%   
Net fx Rs m-6,55727,415 -23.9%   
CASH FLOW
From Operations Rs m3,99421,965 18.2%  
From Investments Rs m-1,433-6,813 21.0%  
From Financial Activity Rs m-3,584-27,305 13.1%  
Net Cashflow Rs m-1,023-8,442 12.1%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 5.1 198.8%  
FIIs % 23.8 23.0 103.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 8.3 185.5%  
Shareholders   102,036 133,026 76.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare GSK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 20, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - UNICHEM LAB COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS